RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.